StockData
MIRA Pharmaceuticals, Inc. logo

MIRA Pharmaceuticals, Inc. (MIRA) company profile

MIRANasdaqPharmaceutical Preparations
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 7/30
$0.29−0.08 (-20.99%)

Close on Nov 20, 2026Market cap $12.23MP/E –Yield –

About MIRA Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on advancing novel oral therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. Its product candidate pipeline comprises Ketamir-2, an NMDA receptor modulator being evaluated for neuropathic and inflammatory pain indications such as chemotherapy-induced peripheral neuropathy; MIRA-55, an oral cannabinoid analog targeting inflammatory pain, anxiety, and cognitive impairment; and SKNY-1, an oral therapeutic candidate aimed at metabolic regulation and craving-related behaviors, including weight management and nicotine dependence. The company operates in the biotechnology and healthcare sector, developing therapies intended for patients suffering from acute and chronic medical conditions.

The company holds exclusive rights to its candidate pipeline across the United States, Canada, and Mexico. Preclinical evaluations and clinical trials are conducted under United States regulatory oversight, with manufacturing development supported by a contract development and manufacturing organization. The company maintains its principal executive offices in Miami, Florida.

Summary of the business section of MIRA Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
MIRA Pharmaceuticals, Inc.
Headquarters
Miami, FL
Address
1200 Brickell Avenue, Suite 1950 #1183 33131
Phone
(813) 369-5150
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Florida
Auditor
SALBERG & COMPANY, P.A., Boca Raton, Florida

Stock & identifiers

Ticker
MIRA
Exchange
Nasdaq
IPO date
Aug 4, 2023
Shares outstanding
42M, Aug 10, 2026
Public float
$15.95M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-1.33 reverse, Mar 28, 2025
SEC CIK
1904286
CUSIP
60458C104
ISIN
US60458C1045
FIGI
BBG01H8XP5F5
Share class FIGI
BBG01H8XP681
LEI
5493000N6HPDY7V7OR15
EIN
85-3354547

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Erez AminovChief Executive Officer, Director3,827,259
Andriy MushakChief Financial Officer–
Alan WeichselbaumChief Financial Officer–
Michelle YanezChief Financial Officer–
Giudice Matthew Paul DelDirector–
Edward Clouston MacPhersonDirector–
Denil Nanji ShekhatDirector22,378
Matthew Pratt WhalenDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Erez Aminov
CEO
$438.75K$242.26K$184.38K$4.42M$19.67K$5.30M+69%
Alan Weichselbaum
Former CFO
$37.00K––$87.30K–$124.30K–
Michelle Yanez
Former CFO
$104.71K–––$12.00K$116.71K-74%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 4, 2023
Securities offered
1,560,000
Exchange
Nasdaq
Lock-up ends (est.)
Jan 31, 2024

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 28, 2026, we had two part time employees and various consultants providing support.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?